Annals of Oncology | VOL. 33

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Publication Date Nov 1, 2022


Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC. Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan-Meier product-limit methodology and compared across groups using the log-rank test. A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (<60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patie...


Treatment For Metastatic Urothelial Cancer Tumour Proportion Score Anti-programmed Cell Death Protein Cooperative Oncology Group Performance Status Eastern Cooperative Oncology Group Performance Cisplatin Ineligible Cisplatin Ineligibility Median Overall Survival Cisplatin-based Chemotherapy Infusion Reaction

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  5

Carbon capture and utilization (CCU) is an emerging technology with commercial potential to convert atmospheric carbon dioxide (CO2) into net zero or ...

Read More

Quality Of Education Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  2

Introduction: The Educational Scholar Program (ESP) is a creative method to focus on the quality of education and the scholarship of education. The ed...

Read More

Gender Equality Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  5

This study deviates from the predominantly feminist/critical school of thought associated with existing gender studies to apply an interpretivist appr...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19


Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.